Cumberland Pharmaceuticals, Inc. (CPIX)
8.49
+0.01
(+0.12%)
USD |
NASDAQ |
Oct 23, 16:00
7.48
-1.01
(-11.90%)
After-Hours: 20:00
Cumberland Pharmaceuticals Enterprise Value : 127.73M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 127.73M |
| October 22, 2026 | 127.58M |
| October 21, 2026 | 122.93M |
| October 20, 2026 | 119.79M |
| October 19, 2026 | 100.91M |
| October 16, 2026 | 108.10M |
| October 15, 2026 | 113.49M |
| October 14, 2026 | 112.74M |
| October 13, 2026 | 107.95M |
| October 12, 2026 | 105.40M |
| October 09, 2026 | 105.85M |
| October 08, 2026 | 105.10M |
| October 07, 2026 | 103.75M |
| October 06, 2026 | 107.50M |
| October 05, 2026 | 106.75M |
| October 02, 2026 | 111.25M |
| October 01, 2026 | 113.04M |
| September 30, 2026 | 117.84M |
| September 29, 2026 | 115.14M |
| September 28, 2026 | 116.19M |
| September 25, 2026 | 114.54M |
| September 24, 2026 | 120.53M |
| September 23, 2026 | 119.49M |
| September 22, 2026 | 123.38M |
| September 21, 2026 | 114.24M |
| Date | Value |
|---|---|
| September 18, 2026 | 110.20M |
| September 17, 2026 | 108.25M |
| September 16, 2026 | 105.10M |
| September 15, 2026 | 100.01M |
| September 14, 2026 | 100.91M |
| September 11, 2026 | 96.26M |
| September 10, 2026 | 97.61M |
| September 09, 2026 | 94.76M |
| September 08, 2026 | 99.71M |
| September 04, 2026 | 102.26M |
| September 03, 2026 | 101.66M |
| September 02, 2026 | 98.21M |
| September 01, 2026 | 98.81M |
| August 31, 2026 | 100.76M |
| August 28, 2026 | 127.28M |
| August 27, 2026 | 130.12M |
| August 26, 2026 | 134.92M |
| August 25, 2026 | 130.87M |
| August 24, 2026 | 117.99M |
| August 21, 2026 | 115.14M |
| August 20, 2026 | 112.89M |
| August 19, 2026 | 115.14M |
| August 18, 2026 | 114.84M |
| August 17, 2026 | 115.59M |
| August 14, 2026 | 117.24M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.903B |
| Corcept Therapeutics, Inc. | 8.967B |
| Veru, Inc. | 15.08M |
| Johnson & Johnson | 662.44B |
| Eli Lilly & Co. | 1.245T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.104M |
| Revenue (Quarterly) | 0.1665M |
| Total Expenses (Quarterly) | 3.273M |
| EPS Diluted (Quarterly) | -0.2854 |
| Profit Margin (Quarterly) | -1.86K% |
| Earnings Yield | -8.59% |
| Normalized Earnings Yield | -8.388 |